JAK2 and acute lymphoblastic leukemia: In contrast to JAK2 p. V617F, the molecular mechanisms by which JAK2 mutations identified ALL disrupt JH2-mediated autoinhibition and facilitate JAK2 dimerization are yet to be fully elucidated (Hammaren et al., 2019a).